Orthofix Med Inc Stock Price, News & Analysis

Orthofix (NASDAQ:OFIX) said President & CEO Massimo Calafiore and CFO Julie Andrews will participate in investor conferences in November 2025: UBS Global Healthcare Conference in Palm Beach Gardens, FL on Nov 11, 2025 at 1:15 PM ET; Stifel Healthcare Conference in New York on Nov 12, 2025 at 10:00 AM ET; and Jefferies Global Healthcare Conference in London on Nov 18–19, 2025 for 1x1 meetings.

Investors can access live and archived webcasts in the Events & Presentations section of Orthofix Investor Relations at ir.orthofix.com. The company also posts updates in the Investors section of orthofix.com.

Orthofix (NASDAQ:OFIX) will release third quarter 2025 financial results on Tuesday, November 4, 2025 before market open.

The company will host a conference call and webcast to review results on November 4, 2025 at 8:30 AM Eastern Time. U.S. dial-in is (888) 596-4144; international dial-in is (646) 968-2525; conference ID 5112586. A webcast and the press release will be available at ir.Orthofix.com.

Orthofix notes it posts investor updates in the Investors section of its website and encourages investors to check www.orthofix.com for official information.

Orthofix (NASDAQ:OFIX) reported its Q2 2025 financial results with pro forma net sales of $200.7 million, representing a 4% increase on a constant currency basis year-over-year. The company posted a net loss of $(14.1) million, or $(0.36) per share.

Key highlights include U.S. Spine Fixation growth of 5%, Bone Growth Therapies sales of $62.6 million (up 6%), and Global Orthopedics sales of $33.3 million with 5% constant currency growth. The company achieved its sixth consecutive quarter of adjusted EBITDA margin expansion, with pro forma adjusted EBITDA of $20.6 million and positive free cash flow of $4.5 million.

Orthofix reaffirmed its full-year 2025 guidance, expecting pro forma net sales between $808-816 million and adjusted EBITDA of $82-86 million.

Orthofix Medical (NASDAQ:OFIX), a global medical technology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will deliver a presentation on Wednesday, August 13, 2025, at 9:00 am Eastern Time.

Investors can access both the live and archived versions of the presentation through the "Events & Presentations" section on Orthofix's Investor Relations website at ir.orthofix.com. The company also maintains regular investor updates on its main website at www.orthofix.com.

Orthofix Medical (NASDAQ:OFIX), a global medical technology company, will release its second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The company will host a conference call and webcast at 8:30 AM ET on the same day.

Investors can join the conference call by dialing (888) 596-4144 in the U.S. or (646) 968-2525 internationally, using conference ID 4830464. The webcast and earnings release will be available on the company's investor relations website.

Orthofix Medical Inc. (NASDAQ:OFIX) has announced the global commercial launch of the TrueLok Elevate Transverse Bone Transport (TBT) System, the first FDA-cleared device in the U.S. for TBT procedures aimed at limb preservation. The system targets bony and soft tissue deformities, particularly diabetic ulcers. With diabetes projected to affect 700 million people globally by 2045 and over 160,000 annual diabetic-related amputations in the U.S., the market opportunity is estimated at $1.2 billion. The device has shown promising results during limited market release with over 130 procedures completed globally. Notably, diabetic foot ulcer patients who undergo amputation face a 57% five-year mortality rate and lifetime healthcare costs exceeding $640,000, making TrueLok Elevate a potentially cost-effective limb-saving solution.

Orthofix Medical Inc. (NASDAQ:OFIX) reported its Q1 2025 financial results with net sales of $193.6 million, representing a 2.7% increase year-over-year. The company posted a net loss of $(53.1) million, or $(1.35) per share. Notable performance includes Bone Growth Therapies sales growth of 5%, Global Orthopedics achieving 11% constant currency growth, and U.S. Spine Fixation growth of 4%.

The company updated its 2025 guidance, now expecting net sales between $808-816 million, while reaffirming non-GAAP adjusted EBITDA guidance of $82-86 million. Pro forma adjusted EBITDA for Q1 was $11.4 million, showing a 200 basis points margin expansion. The company is executing a commercial channel optimization strategy, though this has caused some softness in Biologics and Spine Fixation segments.

Cash position stood at $60.5 million as of March 31, 2025, down from $85.7 million in December 2024, primarily due to annual bonus payments and commissions.

Orthofix Medical (NASDAQ:OFIX) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results.

Participants can join the conference call by dialing (888) 596-4144 in the U.S. and (646) 968-2525 from other locations, using conference ID 7524113. The webcast and earnings release will be available at ir.Orthofix.com.

Orthofix Medical Inc. (NASDAQ:OFIX) has received both FDA 510(k) clearance and European CE Mark for its TrueLok™ Elevate Transverse Bone Transport (TBT) System, marking a significant advancement in limb preservation treatment.

The system, currently in market release in the U.S. and select international markets, addresses bony and soft tissue deformities, including diabetic foot ulcers and nonhealing wounds. It is the first FDA-cleared dedicated system for TBT procedures, enabling surgeons to create and gradually distract bone segments in the tibia.

This innovation targets a $1.2 billion market opportunity, addressing the over 160,000 annual diabetic-related amputations in the U.S. Studies show patients with diabetic foot ulcers who undergo amputation face a 57% five-year mortality rate and lifetime healthcare costs exceeding $640,000 for amputation-related care.